Member Info for Badsterman

Wozzer, I don't think anyone here is "focusing on the person".

Your arguments are being discredited by the failure of any portfolio company to deliver meaningful revenue.

There is already a "consistent framework of audited data" (as you put it), namely - constant fundraising, failed companies and zero profitability.

We are using facts to disprove your AI generated myths.

Wozzer, there is a famous quote; "Those who cannot remember the past are condemned to repeat it".

Cliff has a track record of fundraising, listed companies that don't turn a profit (or worse @BELL) and taking a large salary/bonus each year - all whilst share holders are continually diluted.

There is no evidence to suggest Guident will provide anything other than an exit door for long suffering shareholders. I'm firmly in that camp.

SALT reminds me of BELL (a TEK failure);

Big announcements with no substance, poor sales, constantly raising, CEO promises and hugely overvalued.

It feels like Gross and Rauker have taught Guiney how to milk AIM shareholders.

Come on Guident!!

The £150,000 is within the budgeted spend of the last fundraise. The RNS clearly stated part of the raise was for new evaluations, which ME has now delivered.

Don't people read RNS's?

No,

Your thread is clearly entitled "Placing coming, what we thinking? 0.2"

Why would Valirx raise funds for an evaluation that has nine months before it's even completed and the results known? We all know Val probably have five months cash (debatable) at most.

Your thread title is scaremongering nonsense.

You're an idiot.

The shares in "Newco" would be diluted to provide funding, not Valirx. In any case the agreement is for nine months, by which time Val will have run out of cash anyway.

"IRICoR will establish a Canadian registered, wholly owned, subsidiary ("NewCo")"

READ THE RNS.

LUCY up 30% in pre-market.

Could be interesting....

Dunno what's going on Fred, I can't buy on ii "live quote unavailable" 🤔

Investor Magazine follow Cliff like a lost sheep.

They fail to point out the multiple raises, BELL/LUCY failures, SALT and GENIP share price slippage and the inability of any portfolio company to deliver a meaningful corporate deal.

The special dividend, promised for many years (see annual reports), has not materialised.

I anticipate a huge sell off after the Guident IPO as big investors rush for the exit door because they simply don't trust Cliff anymore. I'll be joining them, hopefully @15p, or more...

Happy New Year!! 🤣

Happy Xmas RNS!

We all know the market likes numbers, so I don't think we'll see a big reaction.

Particularly interesting is that a second optimer is being developed, in enzyme modulation, with positive results already delivered.

👍

Https://valirx.com/activity-updates/eW04pr-strategy-planning

"Strategy Planning

December 10, 2025

We met with one of our Advisory board members, Dr Sheuli Porkess, and her colleague Dr David Montgomery at our Medicity site yesterday. Sheuli and David have cofounded PM Life Sciences Sciences Consulting to help companies like ValiRx and Inaphaea commercialise their assets. Between them, David and Sheuli bring a wealth of big pharmaceutical experience (Boehringer Ingelheim, Pfizer and Ipsen) specifically leveraging their deep life science expertise to provide strategic insight and hands-on operational support to allow pharmaceutical companies to do things differently - smarter, faster and more efficiently. So as ValiRx enters this new chapter of commercialisation, their expertise is perfectly aligned to our mission and will bridge any gaps between our vision and real world implementation of our pipeline into the market - basically helping us get our innovative treatments into the market to reach patients who need them the most and deliver returns to those who have supported their development."

15p would be marvellous.

I've seen Cliff's spin-offs indulging in spending and raising cycles, with no investor returns, for long enough.

Agree with you Aspers, any spike will be a "get out of jail card".

SALT and GENIP have both recently followed the template.

Time to get out of TEK.

Ignore last message, got the wrong end of the stick.

It doesn't say the concert party funded the raise, merely that their holding was diluted.

Apologies.

Not sure what Cliff/Melissa are up too,

The "concert party" detailed in the admission document is TEK Europe (a subsidiary of Tekcapital) and represented by Cliff/Melissa.

Cliff seems to have taken cash out of TEK to fund GENIP (via TEK Europe), he's done that for a reason - your guess is as good as mine.

..another raise, this time GENIP.

At a 45% discount for a paltry £300,000.

Melissa has learned from the master of the fundraise, Cliff.

Late reported trades;

27-Nov-25 16:03:54 0.3031 10,000,000 30.31k O

27-Nov-25 14:41:49 0.285 7,720,000 22.00k O

27-Nov-25 15:36:00 0.3031 10,000,000 30.31k O

27-Nov-25 15:35:49 0.3031 17,000,000 51.53k O

28-Nov-25 15:55:08 0.339 1,902,363 6,449 O

28-Nov-25 15:52:22 0.342 2,922,236 9,994. O

Someone is loading up. 🤔

well lord,

if guident floats at $8.80 and the full amount of shares is taken up , it's mcap will be about £34.5 million (.76 dollar/gbp)

assuming tek retain 70% ownership (i haven't read all the s1's yet) the it would value tek's stake at around £24 million.

now, we all know there is a nav disconnect in play here so i suggest a £40 million mcap for tek, maybe 16-17p.

note: this is *** packet maths, so feel free to comment but don't bust my ⚽️⚽️'s. 🤣

Released 14th November (second amendments to Form S1)

https://www.sec.gov/Archives/edgar/data/2066926/000182912625009141/guidentcorp_s1a2.htm#a_022

Along with 10 other registration documents (see Edgar)

Points to note:

"Approximate date of commencement of proposed sale to public: As soon as practicable after the effective date hereof."

"Common stock offered by us 1,704,545 Shares

Common stock to be outstanding after this offering(1) 4,903,199 shares (or 5,158,881 shares if the underwriters exercise their over-allotment option in full).

Over-allotment option We have granted the underwriters a 45-day option to purchase up to an additional 255,682 shares of our common stock at the initial public offering price to cover over-allotments, if any.

Use of proceeds

We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $12.86 million, based on the assumed initial public offering price of $8.80 per share, which is the midpoint of the price range set forth on the cover page of this prospectus.

The net proceeds received by us from this offering will be used for (1) acceleration of our commercial RMCC platform deployment, (2) launch of our robotics and AV business, (3) research and development, (4) sales and marketing and (5) working capital and general purposes. See “Use of Proceeds.”

Getting close....

There you are Freddie.

I thought you'd choked on your toast, or something. 😄

Yes, I know, it's a modest TEK holding, loss making etc (heard it all).

"In a new key account development, a top-five global logistics company has placed an initial order for Lucyd Armor. They are intending to use Armor to support team connectivity with the Lucyd app's Walkie feature for smartglasses".

The Armor glasses might just save LUCY, my belief is they need a camera in the glasses to really gain traction.